Bloodstream infections can be detrimental to all patient populations, however, in certain patient populations, such as cancer patients, there is an increased risk for poor outcomes. Identification of the pathogen causing the infection coupled with genotypic resistance markers through a rapid multiplex nucleic acid amplification testing (NAT) system can help guide clinicians with proper therapeutic interventions.
In this webinar, Dr. Melvilí Cintrón will discuss considerations for implementing a rapid multiplex NAT system for identifying pathogens and genotypic resistance profiles in bloodstream infections (ePlex® Blood Culture Identification Panels (BCID). She will also provide an overview on how it was integrated within the microbiology laboratory workflow.
In addition, through some case studies from MSKCC, she will detail how well the molecular rapid diagnostic test performs compared to culture while also highlighting how comprehensive the ePlex BCID Panels are in detecting the pathogens causing bloodstream infections.
Melvilí Cintrón, PhD, Assistant Director, Clinical Microbiology Service, Memorial Sloan Kettering Cancer Center
Dr. Melvilí Cintrón is a board-certified clinical microbiologist who currently serves as Assistant Director of the Microbiology Service and Associate Director of the CPEP Clinical Microbiology Fellowship program at Memorial Sloan Kettering Cancer Center (MSKCC). She obtained her bachelor’s degree in industrial biotechnology at the University of Puerto Rico in Mayagüez. She pursued a PhD in Molecular Genetics and Microbiology at Rutgers University where her research focused on elucidating the mechanism of action of toxin-antitoxin systems in Mycobacterium tuberculosis and their potential role in tuberculosis latency. After graduate school, she was a microbiologist at the New Jersey Department of Health and in 2018 she joined MSKCC for her CPEP Clinical Microbiology fellowship training. Her interests include rapid diagnostics, susceptibility testing and applications of total laboratory automation. She is a member of multiple professional organizations and an elected council member of the American Society for Microbiology (ASM) NYC branch.
Who Should Attend?
This webinar will appeal to professionals in the following fields:
- Infectious disease clinicians
- Emergency Department clinicians
- Laboratory directors and managers
- Hospital C-suite
- Sepsis nurses
What You Will Learn
Attendees will gain insights into:
- How to and why integrate rapid molecular diagnostic testing for bloodstream infections in a microbiology laboratory
- How well a rapid molecular diagnostic test for bloodstream infections can correlate to culture while seeing how many pathogens can be detected with a comprehensive panel offering
- Dive into some important cases which can highlight the importance of implementing a rapid diagnostic solution, especially in high-risk populations
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
With the addition of the ePlex® System, Roche expands its portfolio to multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. ePlex® System the true sample-to-answer solution, is designed to optimize laboratory efficiency and address a broad range of infectious disease testing needs, including respiratory, bloodstream and gastrointestinal infections with compact, easy-to-use workstations and self-contained test cartridges. The company’s headquarters are located in Carlsbad, CA.